The TGA, or Therapeutic Goods Administration, is Australia’s regulatory authority for medicines, medical devices, and biological products. It sits within the Australian Department of Health, Disability and Ageing and is responsible for evaluating, approving, and monitoring the safety of health products used by Australians. Think of it as Australia’s equivalent of the FDA in the United States or the EMA in Europe.
What the TGA Actually Does
The TGA’s core job is making sure that therapeutic goods sold in Australia are safe, effective, and manufactured to a high standard. Before a new prescription medicine, vaccine, or medical device can reach Australian patients, the TGA reviews the scientific evidence behind it. This includes data on how well the product works, what side effects it carries, and whether the manufacturing process meets quality standards.
The agency doesn’t stop once a product is approved. It continues monitoring products after they enter the market, looking for safety problems that may not have appeared during clinical trials. If new risks emerge, the TGA can require label changes, restrict how a product is used, or pull it from the market entirely.
Products the TGA Regulates
The TGA’s reach covers a wide range of health products:
- Prescription medicines prescribed by doctors or dentists
- Over-the-counter medicines available from pharmacies
- Complementary medicines including vitamins, herbal products, and traditional medicines
- Medical devices from simple bandages to complex technologies like pacemakers
- Diagnostic tests used to detect diseases or conditions, such as blood tests
- Vaccines, blood products, and other biologicals
Not all products get the same level of scrutiny. Higher-risk products like prescription medicines go through a full evaluation for quality, safety, and effectiveness. Lower-risk products like over-the-counter vitamins are assessed primarily for quality and safety, with less emphasis on proving clinical efficacy. This risk-based approach lets the TGA focus its resources where the potential for harm is greatest.
The Law Behind the TGA
The TGA operates under the Therapeutic Goods Act 1989, which establishes a national system of controls over the quality, safety, efficacy, and timely availability of therapeutic goods used in or exported from Australia. This legislation gives the TGA the legal authority to approve or reject products, conduct inspections, and take enforcement action against companies that break the rules.
How Medicines Are Classified
The TGA uses a scheduling system that determines how you can access different medicines. Schedule 2 medicines (Pharmacy Medicines) are available in pharmacies without a prescription. Schedule 3 medicines (Pharmacist Only) require a pharmacist’s involvement but no prescription. Schedule 4 covers prescription-only medicines, while Schedule 8 applies to controlled drugs with the highest restrictions, such as strong opioid painkillers. This classification directly affects whether you can grab something off a pharmacy shelf or need to visit your doctor first.
How Medical Devices Are Classified
Medical devices follow a separate risk-based classification. Class I devices carry the lowest potential for harm and include simple items like sterile saline eye washes. Classes IIa and IIb represent low-to-moderate and moderate-to-high risk respectively. A catheter designed for short-term use in a peripheral artery, for instance, falls into Class IIa. Class III devices pose the highest risk and include things like catheters used in the central circulatory system or implantable technologies. The higher the classification, the more evidence and oversight the TGA requires before the device can be sold.
How Long Approval Takes
For new prescription medicines, the TGA targets a processing time of around 220 working days from the start of evaluation through to a decision. The statutory maximum is 255 working days. In practice, that means roughly 10 to 12 calendar months. A faster provisional registration pathway exists for medicines that address serious conditions when there’s an unmet need, though it carries the same 220-day target.
Clinical Trials in Australia
Australia has two pathways for running clinical trials with unapproved products. Under the Clinical Trial Notification (CTN) scheme, a company notifies the TGA of a planned trial, but the TGA does not review the trial data beforehand. The responsibility for evaluating safety falls on the institution’s ethics committee. Under the Clinical Trial Approval (CTA) scheme, the TGA reviews scientific data on the product’s quality, preclinical results, and early safety data before the trial can begin. The CTA pathway is mandatory for certain high-risk biological products. In both cases, trials cannot start until an ethics committee has also given approval.
Reporting Side Effects
Once products are on the market, the TGA relies on adverse event reports to catch safety signals. Pharmaceutical companies are legally required to report side effects they learn about. Healthcare professionals, patients, family members, and carers can also submit reports voluntarily through the TGA’s online reporting form or by calling 1300 633 424.
When a report comes in, the TGA assigns it a case number, codes the information, and enters it into its adverse event management system. Two weeks later, a de-identified version of the report appears in the publicly searchable Database of Adverse Event Notifications (DAEN). The TGA uses signal detection methods to analyze patterns across many reports, which can trigger safety reviews, label updates, or product withdrawals.
How the TGA Is Funded
The TGA operates largely on a cost-recovery model, meaning the companies whose products it regulates pay most of the bills. In the 2025-26 financial year, about 73% of funding (roughly $206 million) comes from industry fees and charges. The remaining 27% (about $78 million) comes from government funding. This structure is common among drug regulators worldwide and is designed to ensure the agency has the resources to process applications without relying entirely on taxpayer funding.
International Partnerships
The TGA doesn’t work in isolation. It collaborates with regulators in the United States (FDA), Europe (EMA), the United Kingdom (MHRA), Canada (Health Canada), New Zealand (Medsafe), and Singapore (HSA). One of its most active partnerships is the Access Consortium, a group of five regulators from Australia, Canada, Singapore, Switzerland, and the UK that share the workload of evaluating new medicines. Through initiatives like work-sharing for new active substances and biosimilars, the TGA can draw on assessments completed by comparable overseas regulators, reducing duplication and getting safe products to Australian patients faster.
The TGA also participates in Project Orbis, a framework for collaborative review of promising new cancer treatments across multiple countries, and contributes to international forums like the International Coalition of Medicines Regulatory Authorities and the International Medical Device Regulators Forum.